ClinicalTrials.gg
CompletedNCT01889667Updated Apr 16, 2015Results posted

Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)

A Phase 2 interventional study of ORMD-0801 Dose # 1 and ORMD-0801 Dose # 2 in Diabetes Mellitus Type 2, sponsored by Oramed, Ltd.. Completed at 1 site in United States. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-04-16.

Sponsored by Oramed, Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing insulin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 1 of them phase 3. Insulin · Diabetes Mellitus, Type 2.

Enrollment
38th of 54
30 · median 60
Started
2013
with 4 others
Phase 2
11 of 54
none open now
Registered
30th of 54
by date
Lead sponsor
2 of 54
Oramed, Ltd.

Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, this one is the 38th largest by enrollment, is one of 5 that started in 2013, is one of 11 in phase 2, and was the 30th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing insulin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing insulin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to test the safety and pharmacodynamics of an oral formulation of insulin in subjects with Type 2 Diabetes.

Read the detailed description

This is a single-center, Phase II(a), randomized, double-blind, placebo-controlled, parallel group, inpatient study preceded by a 5-day single-blind outpatient placebo run-in period.

03

Conditions studied

  • Diabetes Mellitus Type 2

Keywords

  • Oral Insulin
  • Diabetes Mellitus Type 2
  • Safety
  • Pharmacodynamics
  • Pharmacokinetics
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients, age 20 to 70 years, inclusive with T2DM;
  • At randomization, patients are treated for diabetes by diet and exercise, or by diet, exercise and metformin (>1000 mg/day; any type and regimen). Patients on a stable regimen of metformin (defined as the same metformin dose and type) for at least 6 weeks prior to entering the placebo run-in period. Other anti-diabetic agents not in use for the 6 weeks prior to entering the placebo run-in period;
  • 25 kg/m2 ≤ ≤ 40 kg/m2
  • 6.5% ≤ ≤ 10.5%, prior to randomization)
  • Fasting plasma glucose ≥ 126 mg/dL (8.3 mmo1/L) prior to randomization;
  • No tobacco or nicotine use within 10 wks prior to screening;
  • Females of must have a negative serum pregnancy test result at screening and a negative urine pregnancy test at Visit 3. Females of non-childbearing potential are defined as who:

    1. had more than 24 months since last menstrual cycle with menopausal levels of FSH;
    2. age > 55 years old; or
    3. are surgically menopausal.

Exclusion criteria

Exclusion Criteria:

  • Presence of any endocrine disease according to the PI;
  • Clinical diagnosis of T1DM;
  • Fasting plasma glucose > 260 mg/dL at the end of washout/stabilization/run-in periods;
  • Evidence of unawareness of hypoglycemia, a documented plasma glucose ≤ 50 mg/dL in the absence of symptoms of hypoglycemia;
  • Presence of any clinically significant condition that might interfere with the evaluation of study medication;
  • Presence or history of cancer within the past 5 yrs. with the exception of adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer;
  • Laboratory abnormalities at screening:

    1. C-peptide \< 1.0 ng/mL;
    2. Positive pregnancy test in females of (at screening and start of run-in period);
    3. Abnormal TSH levels > 1.5 x the ;
    4. Positive test for surface antigen and/or antibody;
    5. Positive test for ;
    6. Any relevant abnormality interfering with the efficacy or the safety assessments during study drug administration;
  • Use of the following medications

    1. History of use of insulin for no more than 1 wk in the last 6 mos and none in the last 6 wks prior to randomization;
    2. History of use of aprotinin at any time prior to the screening visit;
    3. Administration of anti-diabetic drugs other than metformin within 6 wks prior to run-in period;
    4. Administration of thiazolidinedione treatment within 3 months prior to randomization;
    5. Administration of thyroid preparations or thyroxine (except in patients on stable replacement therapy) within 6 weeks prior to screening visit;
    6. Administration of systemic long-acting within two months or prolonged use of other systemic corticosteroids or inhaled corticosteroids within 30 days prior to screening visit;
    7. Use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, and inhaled steroids, beta blockers (with the exception of beta blocker ophthalmic solutions for glaucoma or ocular hypertension), and or immunomodulating agents.
  • History of severe or multiple allergies;
  • History of tobacco or nicotine use within 10 wks prior to screening
  • Patient is on a weight loss program and is not in the maintenance phase, or patient that started weight loss medication within 8 wks prior to screening;
  • Pregnancy or breast-feeding;
  • Patient has a screening visit systolic blood pressure of ≥165 mm Hg or diastolic blood pressure of ≥100 mm Hg. Patients will be allowed to take a BP rescue medication as long as it does not affect glucose metabolism (e.g., diuretics) or sensation of hypoglycemia (e.g., beta-blockers);
  • Patient is, at the time of signing , a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence;
  • Elevated liver enzymes , AST, alkaline phosphatase) > 2 x the upper limit of normal at screening;
  • Very high triglyceride level (>600 mg/dL) at screening;
  • abnormality at screening or CV. Clinically significant CV will include

    1. history of stroke, , or MCI within 6 months prior to screening;
    2. history of or currently have Class II-IV heart failure prior to screening; or
    3. uncontrolled hypertension defined as BP ≥180 mmHg (systolic) or ≥110 mmHG (diastolic) at screening or at Visit 2;
  • One or more to metformin;
  • History of gastrointestinal disorders with the potential to interfere with drug absorption;

At the Principal Investigator's discretion, any condition or other factor that is deemed unsuitable for patient enrollment into the study

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    ORMD-0801 Dose # 1

    Oral Insulin Formulation

    Drug: ORMD-0801 Dose # 1

  • Experimental
    ORMD-0801 Dose # 2

    Oral Insulin Formulation

    Drug: ORMD-0801 Dose # 2

  • Placebo comparator
    Placebo

    Oil Capsules

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate the Safety and Tolerability of ORMD-0801.

    Number of Hypoglycemic events, serious adverse events, and adverse events related to the study drug

    Time frame: Eight (8) days

Secondary outcomes

  1. The Effect of ORMD-0801 on Mean Night Time Glucose as Measured by Contiuous Glucose Monitoring (CGM)

    Difference between concentration of Nightime Glucose of patients on Placebo and concentration of Nightime Glucose of patients on ORMD-0801

    Time frame: Seven (7) days, and last two days (Day 6 and day 7)

  2. The Effect of ORMD-0801 on Mean Daytime Glucose as Measured by Contiuous Glucose Monitoring (CGM)

    Difference between concentration of Mean Daytime Glucose of patients on Placebo and concentration of Mean Daytime Glucose of patients on ORMD-0801

    Time frame: Seven (7) days, and last two days (Day 6 and day 7)

  3. The Effect of ORMD-0801 on Morning Fasting Serum Insulin

    Difference between concentration of Morning fasting serum insulin of patients on Placebo and concentration of Morning fasting C-peptide of patients on ORMD-0801

    Time frame: Screening, Day 2. Day 9

  4. The Effect of ORMD-0801 on Morning Fasting C-peptide Compared to Placebo

    Difference between concentration of Morning fasting C-peptide of patients on Placebo and concentration of Morning fasting C-peptide of patients on ORMD-0801

    Time frame: Screening, Day 2, Day 9

07

Results

Posted Oct 24, 2014

Participant flow

Participant flow — Overall Study
MilestoneORMD-0801 Dose # 1ORMD-0801 Dose # 2Placebo
Started101010
Completed101010
Not completed000

Outcome measures

PrimaryEvaluate the Safety and Tolerability of ORMD-0801.

Number of Hypoglycemic events, serious adverse events, and adverse events related to the study drug

Time frame:
Eight (8) days
Reported as:
Number · Number of Events
Evaluate the Safety and Tolerability of ORMD-0801.
Number of EventsORMD-0801 Dose # 1ORMD-0801 Dose # 2Placebo
Evaluate the Safety and Tolerability of ORMD-0801.000
SecondaryThe Effect of ORMD-0801 on Mean Night Time Glucose as Measured by Contiuous Glucose Monitoring (CGM)

Difference between concentration of Nightime Glucose of patients on Placebo and concentration of Nightime Glucose of patients on ORMD-0801

Time frame:
Seven (7) days, and last two days (Day 6 and day 7)
Reported as:
Mean · mg/DL
The Effect of ORMD-0801 on Mean Night Time Glucose as Measured by Contiuous Glucose Monitoring (CGM)
mg/DLORMD-0801 Dose # 1ORMD-0801 Dose # 2Placebo
Last two days (day 6 and day 7)135.64 ± 39.400150.24 ± 49.264167.95 ± 64.172
All Seven Days139.73 ± 38.861149.38 ± 38.249165.85 ± 60.760
SecondaryThe Effect of ORMD-0801 on Mean Daytime Glucose as Measured by Contiuous Glucose Monitoring (CGM)

Difference between concentration of Mean Daytime Glucose of patients on Placebo and concentration of Mean Daytime Glucose of patients on ORMD-0801

Time frame:
Seven (7) days, and last two days (Day 6 and day 7)
Reported as:
Mean · mg/dL
The Effect of ORMD-0801 on Mean Daytime Glucose as Measured by Contiuous Glucose Monitoring (CGM)
mg/dLORMD-0801 Dose # 1ORMD-0801 Dose # 2Placebo
All Seven Days152.55 ± 36.986163.05 ± 30.282175.99 ± 61.115
Last two days (day 6 and day 7)153.23 ± 40.160158.58 ± 40.672176.06 ± 63.698
SecondaryThe Effect of ORMD-0801 on Morning Fasting Serum Insulin

Difference between concentration of Morning fasting serum insulin of patients on Placebo and concentration of Morning fasting C-peptide of patients on ORMD-0801

Time frame:
Screening, Day 2. Day 9
Reported as:
Mean · mg/dL
The Effect of ORMD-0801 on Morning Fasting Serum Insulin
mg/dLORMD-0801 Dose # 1ORMD-0801 Dose # 2Placebo
Screening20.80 ± 18.98417.34 ± 12.22534.51 ± 64.375
Day 211.93 ± 10.12212.94 ± 7.4729.01 ± 4.665
Day 915.70 ± 8.55915.51 ± 14.9249.85 ± 3.977
SecondaryThe Effect of ORMD-0801 on Morning Fasting C-peptide Compared to Placebo

Difference between concentration of Morning fasting C-peptide of patients on Placebo and concentration of Morning fasting C-peptide of patients on ORMD-0801

Time frame:
Screening, Day 2, Day 9
Reported as:
Mean · mg/dL
The Effect of ORMD-0801 on Morning Fasting C-peptide Compared to Placebo
mg/dLORMD-0801 Dose # 1ORMD-0801 Dose # 2Placebo
Screening4.233 ± 2.38693.125 ± 1.33725.159 ± 4.9825
Day 23.180 ± 1.65933.064 ± 0.92002.400 ± 0.9419
Day 93.875 ± 1.69273.090 ± 1.10212.715 ± 0.8506

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ORMD-0801 Dose # 1—0/10 (0%)3/10 (30%)
ORMD-0801 Dose # 2—0/10 (0%)4/10 (40%)
Placebo—0/10 (0%)5/10 (50%)
Most frequent other events
Most frequent other events
EventORMD-0801 Dose # 1ORMD-0801 Dose # 2Placebo
numberGastrointestinal disorders3/104/105/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)ORMD-0801 Dose # 1ORMD-0801 Dose # 2PlaceboTotal
Mean54.1 ± 4.957.4 ± 4.753.6 ± 12.055.3 ± 6.89
Age, Categorical
Age, Categorical(Participants)ORMD-0801 Dose # 1ORMD-0801 Dose # 2PlaceboTotal
<=18 years0000
Between 18 and 65 years10101030
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)ORMD-0801 Dose # 1ORMD-0801 Dose # 2PlaceboTotal
Female53715
Male57315
Region of Enrollment
Region of Enrollment(participants)ORMD-0801 Dose # 1ORMD-0801 Dose # 2PlaceboTotal
United States10101030
08

Study locations

1 site
  • Orange County Research Center
    Tustin, California 92780, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2013
First posted
Jun 28, 2013
Start
Jun 2013
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results first posted
Oct 24, 2014
Last update
Apr 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01889667
Lead sponsor
Oramed, Ltd.
Collaborators
Integrium
Responsible party
Sponsor
First posted
Jun 28, 2013
Start date
Jun 2013
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Oct 24, 2014
Last update
Apr 16, 2015

Study contacts

Joel M Neutel, M. D.
study director · Orange County Research Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion